Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Dude51on Sep 10, 2020 4:44pm
298 Views
Post# 31538452

To be honest I can't disagree with this posting

To be honest I can't disagree with this postingDevelopment of R-107 for CILI funded under contract with BARDA

The development of R-107 for the treatment of CILI has been funded in whole or in part with federal funds under contract No. HHSO100201600016C from the Biomedical Advanced Research and Development Authority (BARDA). BARDA is a division of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. In 2016, BARDA awarded Salzman Group a $15.9-million (U.S.) contract to develop R-107 as a treatment for CILI as part of continuing preparedness efforts to protect the nation from potential health security threats. An additional $69.9-million (U.S.) could be released to Salzman Group over the next 36 months, as developmental milestones are achieved. The results of the murine study presented above were obtained in 2016 prior to BARDA funding.

Barda liked them enough to give them 15.9 Million dollars. What part are you bashers not understanding?

 

<< Previous
Bullboard Posts
Next >>